SEARCH

SEARCH BY CITATION

References

  • 1
    Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758764.
  • 2
    Bousquet J, Reid J, van Weel C, Baena Cagnani C, Canonica GW, Demoly P et al. Allergic rhinitis management pocket reference 2008. Allergy 2008;63:990996.
  • 3
    Valovirta E, Myrseth SE, Palkonen S. The voice of the patients: allergic rhinitis is not a trivial disease. Curr Opin Allergy Clin Immunol 2008;8:19.
  • 4
    Scadding GK, Williams A. The burden of allergic rhinitis as reported by UK patients compared with their doctors. Rhinology 2008;46:99106.
  • 5
    Blaiss MS. Allergic rhinoconjunctivitis: burden of disease. Allergy Asthma Proc 2007;28:393397.
  • 6
    Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH et al. Keys to successful management of patients with allergic rhinitis: focus on patient confidence, compliance, and satisfaction. Otolaryngol Head Neck Surg 2007;136(Suppl. 6):S107S124.
  • 7
    Zuberbier T, Maurer M, Augustin M. Use of topical steroids is largely restricted by irrational emotional concerns in both patients and physicians. Allergy 2008;63:15601561.
  • 8
    Bastian H, Bender R, Ernst AS, Kaiser T, Kirchner H, Kolominsky-Rabas P et al. Methoden. Version 2.0 vom 19.12.2006. Cologne: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (DE), 2007 (German).
  • 9
    Bundesministerium für Gesundheit und Soziale Sicherung (DE). Bekanntmachung [1883 A] eines Beschlusses des Gemeinsamen Bundesausschusses über eine Verfahrensordnung vom 20.September 2005 [Federal Joint Committee Rules of procedure]. Bundesanzeiger 2005;242:16998 (German).
  • 10
    Bundesministerium für Gesundheit (DE). Gesetz zur Stärkung des Wettbewerbs in der gesetzlichen Krankenversicherung (GKV-Wettbewerbsstärkungsgesetz – GKV-WSG) vom 26.03.2007 [Law to strengthen competition in statutory health insurance]. Bundesanzeiger 2007;66:3613 (German).
  • 11
    Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007;62:10571063.
  • 12
    Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Schäfer I et al. The patient benefit index (PBI) – a novel approach in patient-defined outcomes measurement for skin diseases. Arch Dermatol Res 2009;301:561571.
  • 13
    Bowling A. Measuring disease: a review of disease-specific quality of life measurement scales. Buckingham: Open University Press, 1995.
  • 14
    Lienert G, Raatz U. Testaufbau und Testanalyse. Weinheim: Beltz, 1998.
  • 15
    Teeling Smith G. Measuring health: a practical approach. Chichester: John Wiley, 1988.
  • 16
    Schäfer I, Hacker J, Rustenbach SJ, Radtke M, Franzke N, Augustin M. Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. Eur J Dermatol 2010;20:6267.
  • 17
    Juniper E, Guyatt G. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:7783.
  • 18
    Augustin M, Amon U, Braathen L. Erfassung von Lebensqualitat in der Dermatologie. [Assessment of quality of life in dermatology]. J Dtsch Dermatol Ges 2004;2:802806 (German).
  • 19
    Brazier J, Dixon S. The use of condition specific outcome measures in economic appraisal. Health Econ 1995;4:255264.
  • 20
    Brock D. Quality of life measures in health care and medical ethics. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia: Lippincott-Raven, 1996:487510.
  • 21
    Drummond M, McGuire A. Economic evaluation in health care. Oxford: Oxford University Press, 2001.
  • 22
    Feeny D, Torrance G, Labelle R. Integrating economics evaluations and quality of life assessments. In: SpilkerB, editor. Quality of life and pharmacoeconomics in clinical trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996:8595.
  • 23
    Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis 1987;40:171178.
  • 24
    Kiresuk T, Sherman R. Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J 1968;4:443453.
  • 25
    Steffanowski A, Lichtenberg S, Schmidt J, Huber C, Wittmann WW, Nübling R. Ergebnisqualität psychomatischer Rehabilitaion: Zielerreichungsskalierung auf der Basis einer strukturierten Therapiezielliste [Outcome quality of psychosomatic rehabilitation: goal attainment scaling on the basis of a structured catalogue of therapy goals]. Rehabilitation (Stuttg) 2004;43:219232 (German).